Haemonetics stock
HAENYSEHaemonetics Corporation, HealthcareISIN US4050241003
71Score 71 out of 100, Strong
Price and trend
83 / 100
Price history
+68% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 52% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 57).
The price is 3.7% below its 52-week high. Largest decline in 20 years: 69% (February 2021 to January 2022).
Chart figures for advanced users
- SMA 50$112.91
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$80.98
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)57
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$52.24
- The lowest closing price of the last twelve months.
- Resistance$127.42
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Haemonetics Corporation belongs to the Medical (Devices) industry (United States) and, with a market value of $5.59B, is number 28 of 90 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $1.33B (down 2% year on year) and earnings of $97.31M (down 42%).
- For fiscal 2027, analysts expect on average revenue of $1.42B (up 6.3%) and adjusted earnings per share of $5.31 (up 6.9%).
Show more
- MEQIRI Score 71 out of 100 (Strong): rank 117 of 714 in Healthcare, median 53.
- Our model puts fair value at $121.00, with the price 0% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 292% of earnings over the last 12 months.Fundamentals 84
- Share buybacksShare count down 7% since 2021.Capital allocation 69
Weaknesses
- High debtDebt 1.25 times equity (latest quarter), Medical (Devices) median 0.47.Stability 57
Its standout strengths are momentum and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $86.43 and expensive above $201.66 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 9%. At 10% the fair value would be $101.06, at 8% it would be $150.61.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 26 Sep 2026, revenue rose 4.1% on the twelve months before. Revenue has grown solidly since 2007, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 56%, operating 18%, net 7%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Feb 2027in 84 days
- Last reported
- 5 Nov 2026EPS reported $1.35 (expected $1.29)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $5.310.0%
- Revenue
- $1.42B0.0%
- Earnings per share
- $5.820.0%
- Revenue
- $1.5B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +5.1%Fiscal 2027 guidance raised: reported revenue growth of 5% to 8% and organic growth of 4% to 7%, with adjusted EPS growing in line.
“Accordingly, we are raising our full year reported revenue growth guidance to 5% to 8% and organic growth guidance to 4% to 7%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q1 2027), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Haemonetics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 71
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- GetingeGETI-B.ST $7.6B63
- Shenzhen New Industries Biomedical Engineering300832.SZ $6.9B82
- SectraSECT-B.ST $6.23B79
- APT Medical688617.SS $5.91B81
- LivaNovaLIVN $5.01B66
- Integer HoldingsITGR $4.31B58
- AxoGenAXGN $3.5B46
- AmbuAMBU-B.CO $3.41B70
ETFs that hold Haemonetics
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.23% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.19% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.18% | 0.30% | €2.17B |
Show 5 more
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.17% | 0.30% | €5.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.13% | 0.43% | €2.48B |
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.09% | 0.39% | €188.08M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.09% | 0.30% | €944.34M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.05% | 0.35% | €8.19B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 28 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.